Among the mutations in melanoma, the most frequently observed are the ones with the presence of the BRAF proto‐oncogene serine/threonine‐protein kinase B‐raf (BRAF) or the NRAS proto‐oncogene GTPase (NRAS) activating mutations—accounting for about 50% and 20%–25% of melanomas, respectively [12, 13, 14]. Here, BRAF is linked to melanoma.